Group 1 - Lianhua Technology clarifies that it does not directly produce chlorantraniliprole but provides CDMO services for its advanced intermediates, indicating a limited impact on overall business [1] - The company has a long-term partnership with its client, governed by a framework agreement that restricts product sales and pricing [1] - There has been no notification of increased demand from the client, suggesting stability in the current business model [1] Group 2 - Del Shares announces that its shareholder, Wuxu Value No. 15 Fund, plans to reduce its stake by up to 1.99% through block trading within three months [2] - The reduction is attributed to the shareholder's personal funding needs, which may exert short-term pressure on the stock price [2] - Long-term impacts should be assessed based on the company's fundamentals and core business development [2] Group 3 - Oujing Technology reports that its shareholder, Wanzhao Huigu, intends to reduce its holdings by up to 3% within three months through centralized bidding and block trading [3] - The reduction is for the shareholder's operational needs, with shares sourced from pre-IPO holdings [3] - Similar to Del Shares, this may lead to short-term stock price fluctuations, while long-term effects depend on the company's fundamentals [3]
德尔股份持股5%以上股东拟减持;联化科技:不直接生产氯虫苯甲酰胺 | 新能源早参